Mirum Pharmaceuticals (NASDAQ:MIRM) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM) from a buy rating to a strong-buy rating in a report published on Saturday.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Evercore ISI increased their price objective on Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, TD Cowen upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $102.00.

Mirum Pharmaceuticals Trading Down 1.4%

NASDAQ:MIRM opened at $91.05 on Friday. The company has a market capitalization of $4.68 billion, a P/E ratio of -105.87 and a beta of 0.48. The stock’s 50 day moving average price is $75.05 and its 200 day moving average price is $69.27. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals has a 52 week low of $36.88 and a 52 week high of $93.70.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. The company’s revenue for the quarter was up 47.1% compared to the same quarter last year. On average, research analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MIRM. CWM LLC increased its holdings in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the period. Legal & General Group Plc boosted its position in shares of Mirum Pharmaceuticals by 0.4% during the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after acquiring an additional 176 shares in the last quarter. MCF Advisors LLC increased its stake in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares during the period. Teacher Retirement System of Texas raised its position in Mirum Pharmaceuticals by 2.2% in the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock worth $504,000 after purchasing an additional 215 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its stake in Mirum Pharmaceuticals by 4.2% during the second quarter. Palumbo Wealth Management LLC now owns 5,604 shares of the company’s stock worth $285,000 after purchasing an additional 228 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.